LBPH

Longboard Pharmaceuticals, Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website longboardpharma.com
Employees(FY) 32
ISIN US54300N1037

Performance

+0.07%

+0.95%

+63.75%

+188.88%

+891.21%

YTD

+1281.97%

Profile

Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. Its lead product candidate is LP352, which is in Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. The company's preclinical product candidate includes LP659 which focuses on developing therapies for multiple neurological diseases; and LP143. It also entered into license agreement with Arena Pharmaceuticals Inc. to develop and commercialize LP352, LP659, LP143, and other compounds. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.

Advanced Technical Analysis

Technical Analysis of LBPH 2024-11-20

The stock exhibits a strong bullish sentiment with a Moving Average Score of 90, indicating robust upward momentum, while the Oscillators Score of 36 suggests some bearish pressure that could temper enthusiasm. Overall, the Technical Score of 63 reinforces a generally positive outlook, though caution may be warranted due to the weaker oscillator...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of LBPH

Stock Rank

Recent News & Updates

2024-11-13 07:52
Longboard commences Phase III trial of bexicaserin for DEEs seizure treatment(Clinical Trials Arena)
2024-11-12 08:30
Longboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (DEEs)(Business Wire)
2024-11-11 19:30
Longboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (DEEs)(Businesswire)
2024-11-07 16:01
Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates(Business Wire)
2024-11-07 03:01
Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates(Businesswire)
2024-10-16 06:02
HC Wainwright Downgrades Longboard Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $60 From $80(MT Newswires)
2024-10-15 16:57
Health Care Roundup: Market Talk(The Wall Street Journal)
2024-10-15 10:13
Longboard Set to be Acquired by Lundbeck for $2.6B, Stock Soars 52%(Zacks)
2024-10-15 07:37
B. Riley Downgrades Longboard Pharmaceuticals to Neutral From Buy, Raises Price Target to $60 From $45(MT Newswires)
2024-10-15 05:25
Baird Downgrades Longboard Pharmaceuticals to Neutral From Outperform, Price Target is $60(MT Newswires)
2024-10-15 05:23
Truist Securities Downgrades Longboard Pharmaceuticals to Hold From Buy, Price Target Remains $60(MT Newswires)
2024-10-15 05:06
Lundbeck to acquire Longboard Pharmaceuticals for $2.6bn(Pharmaceutical Technology)
2024-10-14 16:07
Top 1% Biotech Longboard Scores A $2.6 Billion Deal And Skyrockets To A Record(Investor's Business Daily)
2024-10-14 15:45
Lundbeck to acquire Longboard Pharmaceuticals in $2.6B deal(Yahoo Finance Video)
2024-10-14 14:54
Baird Downgrades Longboard Pharmaceuticals to Neutral From Outperform, $60 Price Target(MT Newswires)
2024-10-14 13:57
Top Midday Gainers(MT Newswires)
2024-10-14 11:04
Longboard Pharmaceuticals-H. Lundbeck Deal Undervalues Franchise, Truist Says(MT Newswires)
2024-10-14 09:19
Sector Update: Health Care Stocks Advance Premarket Monday(MT Newswires)
2024-10-14 07:58
Top Premarket Gainers(MT Newswires)
2024-10-14 07:34
Lundbeck to Buy Longboard Pharma in $2.6 Billion Deal(Bloomberg)
2024-10-14 07:00
Longboard Pharmaceuticals Signs $2.6 Billion Deal to be Acquired by Lundbeck(MT Newswires)
2024-10-14 06:39
Denmark's Lundbeck bets on epilepsy drug in $2.6 billion Longboard deal(Reuters)
2024-10-14 06:30
Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline(Business Wire)
2024-10-13 21:34
Why Is Epilepsy Focused Longboard Pharmaceuticals Stock Trading Higher On Monday?(Yahoo Finance)
2024-10-13 18:30
Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline(Businesswire)
2024-10-09 15:50
Longboard Pharmaceuticals Inc (LBPH) Q2 2024 Earnings Call Highlights: Promising Clinical ...(GuruFocus.com)
2024-10-04 16:01
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)(Business Wire)
2024-10-04 04:01
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)(Businesswire)
2024-09-27 04:12
Longboard Pharmaceuticals begins Phase III Dravet syndrome trial(Clinical Trials Arena)
2024-09-26 08:30
Longboard Pharmaceuticals Initiates Phase 3 DEEp SEA Study Evaluating Bexicaserin in Dravet Syndrome(Business Wire)

Page 1 of 7

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.